Actively Recruiting
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Led by Methodist Health System · Updated on 2026-03-20
50
Participants Needed
2
Research Sites
117 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
CONDITIONS
Official Title
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years of age
- Diagnosed with gastroenteropancreatic primary neuroendocrine tumor and consented to undergo PRRT as recommended by the treating physician
- Other primary NETs may be considered if dotatate scan is positive and all other criteria are met
- Metastatic or locally advanced and inoperable tumor
- Clear disease progression on Octreotide within less than 3 years (RECIST 1.1 criteria)
- Disease present within 24 weeks as shown by PET/CT scans with Ga-68 DOTATATE or FDG for high-grade NET transformation
- Well differentiated tumor with Ki67 less than 20%
- Octreotide positive on pathology or lesions with Ga-68 DOTATATE uptake on PET/CT imaging
- Laboratory values: Creatinine less than 1.7, Hemoglobin over 8, White blood cells over 2,000, Platelets over 75,000, Bilirubin less than 3 times the normal limit
- No Octreotide treatment within 30 days before PRRT
- Willing and able to follow the study protocol
- Able to understand and sign the informed consent form in English
You will not qualify if you...
- Do not meet all the above inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Clinical Research Institute at Methodist Health System
Dallas, Texas, United States, 75203
Actively Recruiting
2
Methodist Dallas Medical Center
Dallas, Texas, United States, 75203
Enrolling by Invitation
Research Team
C
Colette N Ndjom, MS
CONTACT
J
Jennifer Kirchner
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here